Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Pre-Tax Margin

Income before tax as a percentage of revenue.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Pre-Tax Margin · Q4 FY2025 · quarter ended Dec 2025

Pre-tax margin widens to -191.2%

Pre-tax margin was -191.2% in Q4 FY2025, up 164.6 pp from a year earlier. Over 3 fiscal years it widened by 207.8 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-191.2%— QoQ
Last fiscal yearDec 2025
-215.3%-175.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+164.6 pp——
1 year-175.0 pp——
3 years+207.8 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-215.3%
Year-over-year change
-175.0pp

Pre-Tax Margin vs competitors

How AAPG compares with its peers on the latest reported figures

  • AAPG's FY2025 pre-tax margin of -215.3% is the 6th highest of the 9 companies compared; the peer median is -125.5%.
  • Its year-over-year change of -175.0 pp is the lowest of 8, against a peer median of +335.5 pp.
  • Over three fiscal years its change of +207.8 pp compares with a peer median of +160.1 pp.
AAPG Competitors Peer median
Pre-Tax Margin for AAPG and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202643.9% +335.5 pp+152.9 pp
ZLABZai Lab LimitedLTM Jun 2026-42.4% +7.3 pp+167.4 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-62.2% +4313.7 pp+63.2 pp
NUVBNuvation Bio Inc.LTM Jun 2026-88.2% +1325.2 pp—
TNGXTango Therapeutics, Inc.FY2025-162.8% +146.4 pp+272.1 pp
AAPGAscentage Pharma Group InternationalFY2025-215.3% -175.0 pp+207.8 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-297.4% -38.1 pp+120.4 pp
VSTMVerastem, Inc.LTM Mar 2026-391.2% +1095.8 pp+2165.7 pp
ANLAdlai Nortye Ltd.LTM Jun 2024-823.1% ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding AAPG) -125.5%+335.5 pp+160.1 pp

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.91M209.71M221.98M980.65M558.48M
Cost of Revenue3.33M22M30.54M29.09M131.73M
Gross Profit24.58M187.71M191.44M951.57M426.75M
Gross Margin88.1%89.5%86.2%97.0%76.4%
Research & Development766.49M743.1M706.97M947.25M1.08B
Selling, General & Admin191.26M328.02M376.46M383.12M522.67M
Operating Expenses957.75M1.04B1.06B1.32B1.61B
Depreciation & Amortization17.18M47.42M93.2M93.17M84.12M
EBITDA(798.34M)(786.97M)(743.61M)(237.63M)(1.1B)
EBITDA Margin-2860.4%-375.3%-335.0%-24.2%-196.1%
Operating Income(869.84M)(849.81M)(872.64M)(369.73M)(1.18B)
Operating Margin-3116.6%-405.2%-393.1%-37.7%-211.1%
Interest Income7.11M9.73M32.41M37.84M79.89M
Interest Expense16.73M52.79M96.06M64.46M52.6M
Other Income / Expenses37.59M(37.36M)(60.23M)(25.53M)(23.21M)
Income Before Tax(832.25M)(887.17M)(932.86M)(395.26M)(1.2B)
Pre-Tax Margin-2981.9%-423.0%-420.2%-40.3%-215.3%
Income Tax Expense(49.83M)(4.25M)(7.15M)10.43M6.75M
Net Income(782.42M)(882.92M)(925.64M)(405.43M)(1.21B)
Net Margin-2803.4%-421.0%-417.0%-41.3%-216.5%
EPS (Basic)(49.12)(53.60)(52.48)(5.36)(13.56)
EPS (Diluted)(49.12)(53.60)(52.48)(5.36)(13.56)
Weighted Avg Shares15.91M16.48M17.64M75.52M89.03M
Weighted Avg Shares (Diluted)15.91M16.48M17.64M75.52M89.03M

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.